Lee Ainslie's CDTX Position Overview
Lee Ainslie (via Maverick Capital LTD) currently holds 0 shares of Cidara Therapeutics, Inc. (CDTX) worth $0, representing 0.00% of the portfolio. First purchased in 2025-Q3, this short-term holding has been held for 3 quarters.
Based on 13F filings, Lee Ainslie has maintained this position in CDTX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 38,428 shares. Largest reduction occurred in Q1 2026, reducing 455,978 shares.
Analysis based on 13F filings available since 2013 Q2
Lee Ainslie's Cidara Therapeutics (CDTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cidara Therapeutics (CDTX) Trades by Lee Ainslie
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -455,978 | Sold Out | 0 | $0.00 |
| Q4 2025 | +38,428 | Add 9.20% | 455,978 | $220.89 |
| Q3 2025 | +417,550 | New Buy | 417,550 | $95.76 |
Lee Ainslie's Cidara Therapeutics Investment FAQs
Lee Ainslie first purchased Cidara Therapeutics, Inc. (CDTX) in Q3 2025, acquiring 417,550 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Lee Ainslie has held Cidara Therapeutics, Inc. (CDTX) for 3 quarters since Q3 2025.
Lee Ainslie's largest addition to Cidara Therapeutics, Inc. (CDTX) was in Q3 2025, adding 417,550 shares worth $39.98 M.
According to the latest 13F filing for Q1 2026, Lee Ainslie's firm, Maverick Capital LTD, owns 0 shares of Cidara Therapeutics, Inc. (CDTX), valued at approximately $0.
As of the Q1 2026 filing, Cidara Therapeutics, Inc. (CDTX) represents approximately 0.00% of Lee Ainslie's publicly disclosed stock portfolio, making it one of their key holdings.
Lee Ainslie's peak holding in Cidara Therapeutics, Inc. (CDTX) was 455,978 shares, as reported at the end of Q4 2025.